



To Our Valued Patients and Health Care Providers:

On September 15, 2019, Purdue reached an agreement in principle on a framework for settling the U.S. opioid litigation facing the Company with 24 state attorneys general, analogous officials from 5 U.S. territories, the Plaintiffs' Executive Committee in the multidistrict litigation (MDL), and co-lead counsel in the MDL. The settlement structure is estimated to provide more than \$10 billion of value to address the opioid crisis.

To implement this settlement and secure a global resolution of all pending litigation, Purdue and all of its subsidiaries have voluntarily filed for reorganization under Chapter 11 of the U.S. Bankruptcy Code. This will have no impact on the availability of our medications and products to patients who need them.

We plan to operate "business as usual." There are no changes planned to Purdue's medications and products or their prices at this time, nor do we anticipate any changes to product names, dosage instructions or other related items as a result of the filing. Any changes that occur in the future would be related to the ordinary course of business.

Filing for chapter 11 is the only way to implement a settlement that can deliver billions of dollars of value and critical help in combatting the opioid addiction crisis for the benefit of the American people and resolve the litigation that we are facing fully and efficiently.

If you have any further questions about our medications, please call 888-726-7535 and select option #1 or visit www.askpurdue.com.

Any questions about the restructuring can be directed to our restructuring information line (844) 217-0912 (or, if you are calling from outside the U.S. or Canada, +1 347-859-8093).

Case documents may also be found at <https://restructuring.primeclerk.com/purduepharma>.